MX2020004374A - Composición farmacéutica para prevenir o tratar la leucemia mieloide aguda o el cáncer de mama metastásico. - Google Patents
Composición farmacéutica para prevenir o tratar la leucemia mieloide aguda o el cáncer de mama metastásico.Info
- Publication number
- MX2020004374A MX2020004374A MX2020004374A MX2020004374A MX2020004374A MX 2020004374 A MX2020004374 A MX 2020004374A MX 2020004374 A MX2020004374 A MX 2020004374A MX 2020004374 A MX2020004374 A MX 2020004374A MX 2020004374 A MX2020004374 A MX 2020004374A
- Authority
- MX
- Mexico
- Prior art keywords
- breast cancer
- myeloid leukemia
- acute myeloid
- metastatic breast
- pharmaceutical composition
- Prior art date
Links
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title abstract 3
- 206010055113 Breast cancer metastatic Diseases 0.000 title abstract 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical class N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 abstract 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170144142 | 2017-10-31 | ||
| PCT/KR2018/013051 WO2019088677A1 (ko) | 2017-10-31 | 2018-10-30 | 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004374A true MX2020004374A (es) | 2020-11-11 |
Family
ID=66333236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004374A MX2020004374A (es) | 2017-10-31 | 2018-10-30 | Composición farmacéutica para prevenir o tratar la leucemia mieloide aguda o el cáncer de mama metastásico. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11370779B2 (https=) |
| EP (1) | EP3705474A4 (https=) |
| JP (1) | JP7005779B2 (https=) |
| KR (1) | KR102247795B1 (https=) |
| CN (1) | CN111542513A (https=) |
| AU (1) | AU2018358582B2 (https=) |
| BR (1) | BR112020008499A2 (https=) |
| CA (1) | CA3080900C (https=) |
| MX (1) | MX2020004374A (https=) |
| PH (1) | PH12020550491A1 (https=) |
| RU (1) | RU2763346C2 (https=) |
| WO (1) | WO2019088677A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12433834B2 (en) | 2019-04-26 | 2025-10-07 | Conopco, Inc. | Hair conditioning composition |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110305056A (zh) * | 2019-05-22 | 2019-10-08 | 西北大学 | 靛玉红新衍生物及其药用用途 |
| CN114521142B (zh) * | 2019-11-04 | 2024-07-02 | Ck雷容股份有限公司 | 用于抑制和/或治疗神经退行性疾病和/或其临床病症的组合物和方法 |
| KR102296440B1 (ko) * | 2019-12-06 | 2021-09-02 | 주식회사 펠레메드 | 신규한 인디루빈 유도체 및 이의 용도 |
| KR102443617B1 (ko) * | 2019-12-06 | 2022-09-16 | 광주과학기술원 | 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물 |
| KR102278176B1 (ko) | 2020-02-20 | 2021-07-16 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조디옥솔 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
| KR20210106155A (ko) | 2020-02-20 | 2021-08-30 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 페닐카르보노히드라조노일 디시아나이드 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
| KR102325607B1 (ko) | 2020-02-20 | 2021-11-12 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
| US20220079934A1 (en) * | 2020-09-17 | 2022-03-17 | Arog Pharmaceuticals, Inc. | Crenolanib for treating pain |
| KR102744517B1 (ko) * | 2022-02-14 | 2024-12-19 | 주식회사 펠레메드 | 신규한 헤테로비시클릭 잔기를 갖는 인디루빈 유도체 및 이의 용도 |
| WO2024181799A1 (ko) * | 2023-02-28 | 2024-09-06 | 주식회사 씨케이리제온 | 신규한 인돌린 유도체 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20010735A2 (en) * | 1999-04-12 | 2002-12-31 | Gerhard Eisenbrand | Indigoid bisindole derivatives |
| FR2850652B1 (fr) * | 2003-01-31 | 2008-05-30 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| KR100588803B1 (ko) | 2004-01-27 | 2006-06-12 | 학교법인조선대학교 | 암세포주에 항암활성을 지닌 인디루빈 유도체 |
| US8552053B2 (en) * | 2005-12-23 | 2013-10-08 | Centre National De La Recherche Scientifique | 7-substituted indirubin-3′oximes and their applications |
| EP2149553B1 (en) * | 2008-08-01 | 2011-10-19 | Centre National de la Recherche Scientifique | 3', 6-substituted indirubins and their biological applications |
| KR101180030B1 (ko) * | 2010-02-05 | 2012-09-05 | 광주과학기술원 | 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체 |
| EP2518139A1 (en) * | 2011-04-27 | 2012-10-31 | Universitätsklinikum Jena | Use of indirubin derivatives for producing pluripotent stem cells |
| US10435367B2 (en) * | 2013-03-14 | 2019-10-08 | City Of Hope | Indirubin derivatives, and uses thereof |
| US20150087687A1 (en) * | 2012-03-23 | 2015-03-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| CA2902914A1 (en) * | 2013-03-14 | 2014-09-25 | City Of Hope | 5-bromo-indirubins |
| US20150259288A1 (en) * | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
-
2018
- 2018-10-30 CA CA3080900A patent/CA3080900C/en active Active
- 2018-10-30 RU RU2020115581A patent/RU2763346C2/ru active
- 2018-10-30 EP EP18873750.6A patent/EP3705474A4/en active Pending
- 2018-10-30 BR BR112020008499-9A patent/BR112020008499A2/pt not_active IP Right Cessation
- 2018-10-30 KR KR1020180131294A patent/KR102247795B1/ko active Active
- 2018-10-30 JP JP2020543443A patent/JP7005779B2/ja active Active
- 2018-10-30 CN CN201880084849.8A patent/CN111542513A/zh active Pending
- 2018-10-30 AU AU2018358582A patent/AU2018358582B2/en active Active
- 2018-10-30 MX MX2020004374A patent/MX2020004374A/es unknown
- 2018-10-30 WO PCT/KR2018/013051 patent/WO2019088677A1/ko not_active Ceased
-
2020
- 2020-04-24 PH PH12020550491A patent/PH12020550491A1/en unknown
- 2020-04-30 US US16/862,923 patent/US11370779B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12433834B2 (en) | 2019-04-26 | 2025-10-07 | Conopco, Inc. | Hair conditioning composition |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200270229A1 (en) | 2020-08-27 |
| CA3080900A1 (en) | 2019-05-09 |
| RU2020115581A (ru) | 2021-12-02 |
| RU2020115581A3 (https=) | 2021-12-02 |
| JP7005779B2 (ja) | 2022-02-10 |
| WO2019088677A1 (ko) | 2019-05-09 |
| JP2021501208A (ja) | 2021-01-14 |
| RU2763346C2 (ru) | 2021-12-28 |
| CA3080900C (en) | 2022-10-25 |
| AU2018358582B2 (en) | 2021-06-10 |
| AU2018358582A1 (en) | 2020-05-07 |
| KR20190049584A (ko) | 2019-05-09 |
| CN111542513A (zh) | 2020-08-14 |
| PH12020550491A1 (en) | 2021-01-11 |
| BR112020008499A2 (pt) | 2020-10-20 |
| EP3705474A1 (en) | 2020-09-09 |
| KR102247795B9 (ko) | 2023-04-12 |
| KR102247795B1 (ko) | 2021-05-04 |
| EP3705474A4 (en) | 2021-06-09 |
| US11370779B2 (en) | 2022-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004374A (es) | Composición farmacéutica para prevenir o tratar la leucemia mieloide aguda o el cáncer de mama metastásico. | |
| MX2018002889A (es) | Compuesto de pirimidina fusionada o sal del mismo. | |
| ECSP18094983A (es) | Derivados de pirazol como inhibidores de la calicreína plasmática | |
| CO2019007839A2 (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
| CO2019008487A2 (es) | Compuesto de quinazolina | |
| CL2018003511A1 (es) | Derivados de pirazolopirimidina como inhibidor de quinasa. | |
| CO2017006230A2 (es) | Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| ECSP20035222A (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa | |
| PH12015502549A1 (en) | Heterocyclic derivatives | |
| MX2020000386A (es) | Inhibidores heterociclicos de la cinasa atr. | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
| PH12016500356A1 (en) | Nsaid and sigma receptor ligand combinations | |
| PH12016501095A1 (en) | Gabapentinoids and sigma receptor ligands combinations | |
| MX2017009246A (es) | Farmaco de combinacion. | |
| PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| MX387726B (es) | Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer. | |
| EA201891439A1 (ru) | Трициклические соединения и их композиции в качестве ингибиторов киназ | |
| MX2019010595A (es) | Derivados de pirrolotriazina como inhibidores de cinasas. | |
| MX2017014463A (es) | Cabazitaxel y su uso para tratar cancer. | |
| MX392672B (es) | Composicion combinada para prevenir o tratar cancer que comprende un derivado de benzofenona tiazol como un vda e inhibidor de topoisomerasa. | |
| HK1233917A1 (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
| BR112017012355A2 (pt) | composição farmacêutica compreendendo composto amida heterocíclica aromática contendo nitrogênio bicíclico como ingrediente ativo |